This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Kodiak Sciences (KOD) Q4 Loss Widens, Eye Candidate in Focus
by Zacks Equity Research
Kodiak Sciences (KOD) reports a wider-than-expected loss for the fourth quarter of 2021. It is focusing on the lead candidate, KSI-301, being developed for treating various retinal vascular diseases.
Why Kodiak Sciences (KOD) Might Surprise This Earnings Season
by Zacks Equity Research
Kodiak Sciences (KOD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Here's Why Kodiak Sciences Inc. (KOD) is Poised for a Turnaround After Losing 82.3% in 4 Weeks
by Zacks Equity Research
Kodiak Sciences Inc. (KOD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Kodiak (KOD) Completes Enrolling Patients in Retina-Based Studies
by Zacks Equity Research
Kodiak Sciences (KOD) has enrolled more than 900 patients in two phase III studies evaluating its VEGF inhibitor in patients with DME.
Kodiak Sciences (KOD) Focuses on Developing Eye Candidate KSI-301
by Zacks Equity Research
Kodiak Sciences (KOD) progresses well with the development of its lead candidate, KSI-301, for treating various retinal vascular diseases. Stiff competition in the target market remains a woe.
Kodiak Sciences (KOD) Q3 Loss Widens, Eye Candidate in Focus
by Zacks Equity Research
Kodiak Sciences (KOD) reports wider-than-expected loss for the third quarter of 2021. Pipeline development remains in focus for the company.
Kodiak Sciences Inc. (KOD) Up 15.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kodiak Sciences (KOD) Q2 Earnings Lag, Eye Candidate in Focus
by Zacks Equity Research
Kodiak Sciences (KOD) reports wider-than-expected loss for the second quarter of 2021. Pipeline development remains in focus for the company.
Why Is Kodiak Sciences Inc. (KOD) Down 4% Since Last Earnings Report?
by Zacks Equity Research
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kodiak Sciences (KOD) Q1 Earnings Miss, KSI-301 in Focus
by Zacks Equity Research
Kodiak Sciences (KOD) reports wider-than-expected loss for the first quarter of 2021. Pipeline development remains in focus for the company.
Cigna (CI) to Post Q1 Earnings: Will It Deliver a Beat?
by Zacks Equity Research
Cigna (CI) Q1 results are likely to reflect better revenues but a weak bottom line.
What's in Store for Select Medical (SEM) Earnings in Q1?
by Zacks Equity Research
Select Medical (SEM) Q1 results are likely to reflect improvement in patient volumes.
Repligen (RGEN) Beats on Q1 Earnings & Sales, Raises 2021 View
by Zacks Equity Research
Repligen (RGEN) reports encouraging first-quarter results with sales and earnings beating estimates. The company also raises its guidance for 2021. Stock up.
What Makes Kodiak Sciences Inc. (KOD) a New Buy Stock
by Zacks Equity Research
Kodiak Sciences Inc. (KOD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Kodiak Sciences (KOD) Misses on Q4 Earnings, KSI-301 in Focus
by Zacks Equity Research
Kodiak Sciences (KOD) reports wider-than-expected loss in the fourth quarter of 2020. The company is making good progress with the development of its lead pipeline candidate, KSI-301.
Kodiak (KOD) Closes Enrollment in Phase IIb/III Wet AMD Study
by Zacks Equity Research
Kodiak Sciences (KOD) completes recruitment in the pivotal phase IIb/III DAZZLE study, currently evaluating KSI-301 for the treatment of patients with wet age-related macular degeneration.
Kodiak Sciences (KOD) Q3 Earnings Miss, KSI-301 in Focus
by Zacks Equity Research
Kodiak Sciences (KOD) reports wider-than-expected loss in the third quarter of 2020. The company is progressing well with the development of its lead pipeline candidate KSI-301.
Why Kodiak Sciences (KOD) Stock Might be a Great Pick
by Zacks Equity Research
Kodiak Sciences (KOD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Kodiak Sciences Inc. (KOD) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Kodiak Sciences Inc. (KOD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Kodiak Sciences' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Kodiak Sciences
Biotech Rally Sends Nasdaq to 9000: ETFs in Focus
by Sanghamitra Saha
Some biotech stocks have contributed materially to the Nasdaq's 1000-point gain since Aug 27, 2018 and helped it notch a record 9,000 on Dec 26.
Is Kodiak Sciences (KOD) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (KOD) Outperforming Other Medical Stocks This Year?
Kodiak Sciences Inc. (KOD) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Kodiak Sciences Inc. (KOD) have what it takes to be a top stock pick for momentum investors? Let's find out.
Will Kodiak Sciences Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Kodiak Sciences.
Surging Earnings Estimates Signal Upside for Kodiak Sciences Inc. (KOD) Stock
by Zacks Equity Research
Kodiak Sciences Inc. (KOD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.